How should hypercalcemia be managed in a patient being evaluated for multiple myeloma who has acute kidney injury with a glomerular filtration rate of approximately 20 mL/min?

Management of Hypercalcemia in Multiple Myeloma with AKI and GFR 20

Immediately initiate aggressive IV normal saline hydration targeting urine output of 100-150 mL/hour, followed by IV zoledronic acid 4 mg (dose-adjusted for renal impairment) infused over at least 15 minutes, while simultaneously starting anti-myeloma therapy with daratumumab plus bortezomib/cyclophosphamide/dexamethasone. 1, 2

Immediate Fluid Resuscitation

Aggressive IV saline is the cornerstone of initial management to correct hypovolemia and promote calciuresis. 1, 2

• Administer IV normal saline to achieve urine output >3 L/day (or 100-150 mL/hour). 1, 2
• Monitor fluid status carefully to avoid hypervolemia, especially critical given the GFR of 20. 1
• Do NOT use loop diuretics (furosemide) until complete volume repletion is achieved. 1, 2 Loop diuretics before adequate hydration will worsen dehydration and hypercalcemia. 3
• Loop diuretics should only be added if signs of fluid overload develop after full rehydration. 1, 2

The rationale: hypercalcemia causes polyuria and volume contraction, which reduces GFR and increases renal calcium reabsorption, creating a vicious cycle. 1 Rehydration breaks this cycle.

Bisphosphonate Therapy (Dose-Adjusted for Renal Function)

Zoledronic acid is the preferred bisphosphonate but requires dose adjustment at GFR 20. 1, 2, 4

• For creatinine clearance <60 mL/min, reduce zoledronic acid dose according to FDA labeling. 4
• Standard dose is 4 mg IV over ≥15 minutes for CrCl >60 mL/min. 4
• For CrCl 30-60 mL/min: reduce to 3.5 mg; for CrCl 10-30 mL/min: reduce to 3.0 mg. 4
• Measure serum creatinine before each dose and withhold if renal function deteriorates. 1, 2
• Bisphosphonates normalize calcium in ~50% of patients by day 4. 1, 2

Alternative: Consider denosumab 120 mg subcutaneously if renal function is too impaired for bisphosphonates. 1, 2 Denosumab has lower renal toxicity but higher risk of hypocalcemia. 1, 2

• If using denosumab, provide calcium 500 mg plus vitamin D 400 IU daily supplementation. 2
• Monitor for hypocalcemia closely with denosumab. 2

Adjunctive Calcitonin for Rapid Effect

Calcitonin provides rapid calcium reduction within hours but has limited duration. 2

• Administer calcitonin-salmon 100 IU subcutaneously or intramuscularly every 12 hours. 2
• Use as a bridge until bisphosphonates take effect (typically 2-4 days). 2
• Calcitonin's effect is modest and tachyphylaxis develops within 48 hours. 2

Corticosteroids (Myeloma-Specific)

Corticosteroids are particularly effective in multiple myeloma-associated hypercalcemia. 1, 2

• Administer dexamethasone 20-40 mg IV daily as part of anti-myeloma regimen. 1, 2
• Corticosteroids reduce intestinal calcium absorption and are synergistic with bisphosphonates in myeloma. 1, 2

Anti-Myeloma Therapy (Critical for Definitive Control)

Rapid reduction of tumor burden is essential for long-term calcium control and renal recovery. 1

• Preferred regimen: Daratumumab plus bortezomib/cyclophosphamide/dexamethasone (Dara-VCD). 1
• Bortezomib and cyclophosphamide do not require dose adjustment for renal impairment. 1
• Daratumumab hastens response and limits duration of extracorporeal light chain removal needed. 1
• Avoid lenalidomide initially due to required dose adjustments in renal failure. 1

The goal is to reduce circulating free light chains as quickly as possible to prevent further renal damage. 1

Plasmapheresis Consideration

Consider daily plasmapheresis to rapidly reduce free light chains and improve renal recovery. 1

• Perform daily until involved free light chain <150 mg/dL or >60% reduction from baseline. 1
• Plasmapheresis improves renal recovery rates and may improve overall survival in patients whose renal function recovers. 1
• Administer daratumumab AFTER plasmapheresis to avoid removing the antibody. 1
• Alternative: High-cutoff hemodialysis (if available) can reduce free light chains by >70%. 1

Dialysis for Severe Renal Failure

Hemodialysis with low-calcium dialysate is reserved for severe hypercalcemia with oliguria or refractory cases. 1, 2

• Use calcium-free or low-calcium dialysate (1.25-1.50 mmol/L or 1.5-2.0 mEq/L). 1, 2
• Dialysis effectively removes calcium through diffusive therapy. 1, 2
• Consider dialysis if calcium remains >14 mg/dL despite aggressive medical therapy or if oliguria develops. 2

Critical Medications to AVOID

Immediately discontinue all nephrotoxic agents and calcium-containing medications. 1, 2

• Stop NSAIDs, which worsen renal function. 1, 2
• Avoid IV contrast media unless absolutely necessary. 1
• Discontinue all calcium supplements and vitamin D supplements. 2
• Stop calcium-based phosphate binders if patient was taking them. 2

Monitoring Parameters

Intensive monitoring is required during acute management. 1, 2

• Check ionized calcium every 4-6 hours for first 48-72 hours, then twice daily until stable. 2
• Monitor serum creatinine, BUN, electrolytes (especially potassium and magnesium) every 6-12 hours. 1, 2
• Obtain 12-lead ECG to assess for shortened QT interval and arrhythmias. 2
• Target corrected calcium of 8.4-9.5 mg/dL (lower end of range preferred). 2
• Monitor for hypocalcemia after treatment, especially if using denosumab. 2

Renal Recovery Prognosis

Renal function may recover in >50% of patients, usually within first 3 months. 1

• Recovery of renal function improves overall survival. 1
• Aggressive treatment of hypercalcemia and rapid reduction of free light chains maximizes chance of renal recovery. 1
• High-dose chemotherapy with autologous stem cell transplant can be safely performed after renal recovery, even in patients who required dialysis. 1

Common Pitfalls to Avoid

• Never give loop diuretics before adequate volume repletion – this worsens hypercalcemia and renal function. 1, 2, 3
• Do not delay bisphosphonate therapy waiting for complete rehydration – start early for faster calcium reduction. 2
• Do not use full-dose zoledronic acid at GFR 20 – dose reduction is mandatory to prevent further renal injury. 4
• Do not forget to supplement calcium/vitamin D if using denosumab – risk of severe hypocalcemia is high. 2
• Do not use lenalidomide as initial therapy – requires dose adjustment and may worsen renal function. 1